{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"PROBE","nct_id":"NCT04510597","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=probe-nct04510597. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PROBE","arms":[{"description":"Nivolumab 240 mg IV 1 q 2 weeks\n\nOR\n\nNivolumab 480 mg IV 1 q 4 weeks\n\nOR\n\nPembrolizumab 200 mg IV 1 q 3 weeks Axitinib 5 mg oral Daily BID\n\nOR\n\nAvelumab 10 mg/kg IV 1 q 2 weeks Axitinib 5 mg oral Daily BID","label":"Arm 1: Continued Systemic Therapy Only","type":"ACTIVE_COMPARATOR"},{"description":"Continued systemic therapy as above, plus:\n\nRadical or partial nephrectomy may be performed using laparoscopic, open, or robotic approaches. Surgery should be performed within 8 weeks of randomization.","label":"Arm 2: Nephrectomy and Continued Systemic Therapy","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2033-07","type":"ESTIMATED"},"conditions":["Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":{"count":364,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Cytoreductive Nephrectomy","otherNames":[],"type":"PROCEDURE"},{"name":"Active Comparator","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-08","lead_sponsor":"SWOG Cancer Research Network","official_title":"Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2033-07","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"From date of randomization to date of death due to any cause, assessed up to 7 years."}],"references":[{"citation":"Bell H, Cotta BH, Salami SS, Kim H, Vaishampayan U. \"PROBE\"ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer. Kidney Cancer J. 2022 Mar 15;6(1):3-9. doi: 10.3233/kca-210010.","pmid":"35310961","type":"DERIVED"},{"citation":"Kuusk T, Abu-Ghanem Y, Mumtaz F, Powles T, Bex A. Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Curr Opin Urol. 2021 May 1;31(3):262-269. doi: 10.1097/MOU.0000000000000868.","pmid":"33742979","type":"DERIVED"}],"start_date":{"date":"2021-03-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial","url":"https://clinicaltrials.gov/study/NCT04510597"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/probe-nct04510597"}